Drugs / factor VIII
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT04621916 Comparator | Sep 2020 → Sep 2024 | hemophilia A | Children's Hospital Los Angeles | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | factor VIII | “Group 1 will receive ongoing once per weekly factor VIII therapy along with emicizumab after completion of a successful ITI.” NCT04621916 ↗ |
| Known as | FVIII | “Treatment consists of replacing the missing FVIII with FVIII clotting factor concentrates.” NCT04621916 ↗ |
| Action | Restore | “Treatment consists of replacing the missing FVIII with FVIII clotting factor concentrates.” NCT04621916 ↗ |
| Modality | Protein / enzyme biologic | “FVIII clotting factor concentrates” NCT04621916 ↗ |
| Route | Intravenous | “the need for repeated intravenous infusions” NCT04621916 ↗ |